753 related articles for article (PubMed ID: 28919303)
21. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.
Hoornenborg E; Coyer L; Achterbergh RCA; Matser A; Schim van der Loeff MF; Boyd A; van Duijnhoven YTHP; Bruisten S; Oostvogel P; Davidovich U; Hogewoning A; Prins M; de Vries HJC;
Lancet HIV; 2019 Jul; 6(7):e447-e455. PubMed ID: 31178284
[TBL] [Abstract][Full Text] [Related]
22. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
23. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
[TBL] [Abstract][Full Text] [Related]
24. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
[TBL] [Abstract][Full Text] [Related]
25. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
[TBL] [Abstract][Full Text] [Related]
26. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
27. Unsupervised PrEP in routine practice: a new challenge?
Laroche H; Lions C; Zaegel-Faucher O; Tamalet C; Poizot-Martin I
Int J STD AIDS; 2019 Jun; 30(7):715-717. PubMed ID: 30975069
[TBL] [Abstract][Full Text] [Related]
28. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
[TBL] [Abstract][Full Text] [Related]
29. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
[TBL] [Abstract][Full Text] [Related]
30. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project.
Wijstma ES; Jongen VW; Boyd A; van den Elshout MAM; de Vries HJC; Davidovich U; Anderson PL; Prins M; Hoornenborg E; Schim van der Loeff MF
AIDS; 2024 Jul; 38(8):1248-1256. PubMed ID: 38518076
[TBL] [Abstract][Full Text] [Related]
31. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
Jongen VW; Hoornenborg E; van den Elshout MA; Boyd A; Zimmermann HM; Coyer L; Davidovich U; Anderson PL; de Vries HJ; Prins M; Schim van der Loeff MF;
J Int AIDS Soc; 2021 May; 24(5):e25708. PubMed ID: 33973373
[TBL] [Abstract][Full Text] [Related]
32. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
[TBL] [Abstract][Full Text] [Related]
33. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG;
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405
[TBL] [Abstract][Full Text] [Related]
34. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Donnell D; Baeten JM; Bumpus NN; Brantley J; Bangsberg DR; Haberer JE; Mujugira A; Mugo N; Ndase P; Hendrix C; Celum C
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):340-8. PubMed ID: 24784763
[TBL] [Abstract][Full Text] [Related]
35. Emtricitabine/tenofovir alafenamide (Descovy) for HIV.
Med Lett Drugs Ther; 2016 Aug; 58(1500):100-1. PubMed ID: 27466750
[No Abstract] [Full Text] [Related]
36. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
[TBL] [Abstract][Full Text] [Related]
37. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
38. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
39. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
Hoornenborg E; Achterbergh RC; van der Loeff MFS; Davidovich U; van der Helm JJ; Hogewoning A; van Duijnhoven YT; Sonder GJ; de Vries HJ; Prins M;
J Int AIDS Soc; 2018 Mar; 21(3):e25105. PubMed ID: 29603900
[TBL] [Abstract][Full Text] [Related]
40. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
